February 2024

Business and practice updates from our Strategic Alliance Partners.

Coverage from the Institute for Value-Based Medicine event with the University of Kansas Cancer Center in Kansas City, Kansas.

Coverage from the Institute for Value-Based Medicine event in Tampa, Florida, with Moffitt Cancer Center.

Coverage in the February 2024 issue of Evidence-Based Oncology.

The January 2024 guidelines update also changed mirvetuximab soravtansine plus bevacizumab from a category 2B recommendation to a category 2A recommendation for platinum-resistant, FRα-expressing tumors.

An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in patients with locally advanced, unresectable non­­–small cell lung cancer (NSCLC).

Findings from PREVENT-HF put to rest the idea that once remodeling in the heart's structure starts following anthracyclines that nothing can be done to treat it.